Zika Vaccine Preclinical Studies Produced Promising Results
The ability of the Zika virus to cross the placental and blood-brain barriers to cause severe neurological disorders in developing fetuses makes the development of vaccines to prevent Congenital Zika Syndrome (CZS) an urgent global health priority, wrote researchers in a peer-reviewed study published by the journal NPJ Vaccines - Nature on Feb. 17, 2022.
In the current study, both prime and prime-boost vaccination with the ZPIV vaccine candidate provided 80% efficacy in protection against fetal malformations after ZIKV infection during pregnancy in C57BL/6 mice.
Importantly, neutralizing antibody titers correlated with protecting dams and fetuses against ZIKV infection.
ZPIV also is safe in healthy non-pregnant humans.
Because of its expected safety profile, inactivated virus vaccines, including ZPIV adjuvanted with aluminum hydroxide, would be a potentially favored platform for vaccinating pregnant women.
This aspect was not examined in the current study.
Further preclinical studies are necessary to investigate the efficacy of ZPIV vaccination during pregnancy.
Zika News publishes updated vaccine development news.